Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
NCT ID: NCT01916837
Last Updated: 2013-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2010-02-28
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
NCT07093775
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
NCT05906407
"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"
NCT06871501
Recurrence Risk Evaluation by 21-gene Detection
NCT03841266
Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer
NCT00912080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
Sampling of tumor tissue
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Sampling of tumor tissue after breast cancer surgery
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Sampling of tumor tissue after breast cancer surgery
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sampling of tumor tissue
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Sampling of tumor tissue after breast cancer surgery
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
Sampling of tumor tissue after breast cancer surgery
Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T1, T2, or operable T3 disease
* Zero to three positive lymph nodes and no distant metastases
* Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance
Exclusion Criteria
* No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jules Bordet Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Jules Bordet
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delree P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart M, Sotiriou C. Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One. 2013 Aug 19;8(8):e66848. doi: 10.1371/journal.pone.0066848. eCollection 2013.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-015521-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1668
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.